

Resource Summary Report

Generated by [NIF](#) on Aug 2, 2026

NOD.Cg-Prkdc^{scid} Il2rg/SzJ

RRID:IMSR_JAX:005557

Type: Organism

Proper Citation

RRID:IMSR_JAX:005557

Organism Information

URL: <https://www.jax.org/strain/005557>

Proper Citation: RRID:IMSR_JAX:005557

Description: Mus musculus with name NOD.Cg-Prkdc^{scid} Il2rg/SzJ from IMSR.

Species: Mus musculus

Synonyms: NOD-scid IL2Rg. NSG. NOD scid gamma. NOD-scid IL2Rgamma

Notes: gene symbol note: interleukin 2 receptor; gamma chain|protein kinase; DNA activated; catalytic polypeptide; mutant strain|congenic strain: Il2rg|Prkdc

Affected Gene: interleukin 2 receptor; gamma chain|protein kinase; DNA activated; catalytic polypeptide

Genomic Alteration: targeted mutation 1; Warren J Leonard|severe combined immunodeficiency

Catalog Number: JAX:005557

Database: JAX Mice and Services

Database Abbreviation: JAX

Availability: live

Organism Name: NOD.Cg-Prkdc^{scid} Il2rg/SzJ

Record Creation Time: 20250513T053650+0000

Record Last Update: 20260801T050353+0000

Ratings and Alerts

- Used for genotyping by the Human Islet Research Network community. Contact(s): Seung Kim, Simona Chera, Pedro Herrera, Charles Chang - Human Islets Research Network <https://hirnetwork.org/>

No alerts have been found for NOD.Cg-Prkdc^{scid} Il2rg/SzJ.

Data and Source Information

Source: [Integrated Animals](#)

Source Database: JAX Mice and Services

Usage and Citation Metrics

We found 908 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Yuan F, et al. (2026) Glioblastoma stem cells resist cuproptosis with circadian variation of copper levels. The Journal of clinical investigation, 136(1).

Yu KKH, et al. (2026) Characterization of a pathogenic subpopulation of human glioma associated macrophages linked to glioma progression. Cancer cell, 44(1), 129.

Tebas P, et al. (2026) Clinical Trial Results Provide the Rationale to Protect Dual HIV-specific T Cells with a Signaling-Defective HIV Fusion Inhibitor. Molecular therapy : the journal of the American Society of Gene Therapy.

Castelli S, et al. (2026) IL-9 signaling redirects CAR T cell fate toward CD8+ memory and CD4+ cycling states, enhancing antitumor efficacy. Immunity, 59(1), 195.

Galeano Niño JL, et al. (2026) Tumor-infiltrating bacteria disrupt cancer epithelial cell interactions and induce cell-cycle arrest. Cancer cell, 44(1), 166.

Saleem SK, et al. (2025) JNK1 inhibitors target distal B cell receptor signaling and overcome BTK-inhibitor resistance in CLL. The Journal of experimental medicine, 222(1).

Kim KY, et al. (2025) Establishment and Its Utility of a Patient-Derived Cell Xenografts (PDCX) Model with Cryopreserved Cancer Cells from Human Tumor. Cells, 14(5).

Dobersch S, et al. (2025) HMGA2 and protein leucine methylation drive pancreatic cancer lineage plasticity. Nature communications, 16(1), 4866.

Yan W, et al. (2025) Targeted editing of CCL5 with CRISPR-Cas9 nanoparticles enhances breast cancer immunotherapy. Apoptosis : an international journal on programmed cell death, 30(3-4), 912.

Hughes KA, et al. (2025) Oleic Acid Integrated Acetalated Dextran Nanoparticles for Enhanced Chemotherapeutic Delivery to the Bone Marrow. ACS applied materials &

interfaces, 17(45), 61799.

Deb SP, et al. (2025) Oncogenic p53 induces mitotic errors in lung cancer cells by recopying DNA replication forks conferring targetable proliferation advantage. Research square.

Chen XL, et al. (2025) Ovarian Tumor FAK Inhibition Releases Omega-3 Fatty Acids Stimulating GATA6 Peritoneal Macrophage CXCL13 Production Enhancing Immunotherapy. bioRxiv : the preprint server for biology.

Elhamamsy A, et al. (2025) Hypoxic stress incites HIF1 α -driven ribosome biogenesis that can be exploited by targeting RNA Polymerase I. Nature communications, 16(1), 8018.

Wang L, et al. (2025) Targeting CHEK1: Ginsenosides-Rh2 and Cu₂O@G-Rh2 nanoparticles in thyroid cancer. Cell biology and toxicology, 41(1), 30.

Hu X, et al. (2025) Enhanced homing and efficacy of HER2-CAR T cells via CXCR5/CCR6 co-expression for HER2-positive NSCLC. Journal of translational medicine, 23(1), 863.

Ran X, et al. (2025) PARP inhibitor radiosensitization enhances anti-PD-L1 immunotherapy through stabilizing chemokine mRNA in small cell lung cancer. Nature communications, 16(1), 2166.

Zhang T, et al. (2025) The effect of deuterated PLK1 inhibitor on its safety and efficacy in vivo. Frontiers in oncology, 15, 1510052.

Vick EJ, et al. (2025) Targeting of IRAK4 and GSPT1 enhances therapeutic efficacy in AML via c-Myc destabilization. Leukemia, 39(9), 2163.

Andersch L, et al. (2025) Investigating genetic modifications to enhance L1CAM-CAR T cell migration in solid tumors in a 3D bioprinted neuroblastoma model. Frontiers in immunology, 16, 1677361.

Wang Y, et al. (2025) Increased Atherosclerosis in HIV-Infected Humanized Mice Is Caused by a Single Viral Protein, Nef. The Journal of infectious diseases, 232(1), e116.